Amgen

$233.77
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.36 (+0.15%) Today
$0.00 (0.00%) As of 8:00 PM EST after-hours

Why Robinhood?

You can buy or sell Amgen and other stocks, options, ETFs, and crypto commission-free!

About AMGN

Amgen Inc. Common Stock, also called Amgen, is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Read More Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Employees
21,500
Headquarters
Thousand Oaks, California
Founded
1980
Market Cap
138.69B
Price-Earnings Ratio
17.91
Dividend Yield
2.71
Average Volume
1.98M
High Today
$235.00
Low Today
$233.19
Open Price
$234.68
Volume
1.83M
52 Week High
$235.80
52 Week Low
$166.30

Collections

AMGN News

ReutersDec 6

UPDATE 1-FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

(Adds background, analyst comment) Dec 6 (Reuters) - The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson'
746
ReutersDec 3

Pharmacy benefits manager Abarca inks discount deal for Amgen's Enbrel

FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California in this October 21, 2013. REUTERS/Robert Galbraith/Files (Reuters)
7
BenzingaDec 3

Abarca, Amgen Enter Outcome-Based Agreement For Enbrel

AVENTURA, Fla., Dec. 3, 2019 /PRNewswire/ -- Abarca, a pharmacy benefit manager (PBM) that is disrupting the industry with an entirely new approach to technolog
0

AMGN Earnings

$3.22
$3.47
$3.72
$3.97
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
Expected Jan 28, After Hours

You May Also Like

More AMGN News

CNBCDec 2

Cramer's lightning round: I think you want to sell some Caterpillar

Biogen: An analyst said earlier Monday that Biogen's Alzheimer's drug "is going to be a bust and that makes it so that I am concerned because there's no reason
413
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.
Search
LearnBlogCareersHelpLog InSign Up